39 Participants Needed

Bevacizumab + Chemoimmunotherapy + Atezolizumab for Small Cell Lung Cancer

(BELIEVE Trial)

Recruiting at 2 trial locations
AO
Overseen ByAmy Oppenheim
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: * In patients with ES-SCLC with liver metastases, can bevacizumab in combination with atezolizumab and chemotherapy prolong the length of time that the cancer does not progress? * Is bevacizumab safe and tolerable when combined with atezolizumab and chemotherapy in patients with ES-SCLC and liver metastases? The study treatment includes two phases: * Induction phase: bevacizumab will be administered in combination with atezolizumab and chemotherapy on a 21-day cycle for four cycles. * Maintenance: atezolizumab and bevacizumab will be administered every 21 days for up to 12 months, or until unacceptable toxicity or disease progression. Participants will undergo blood tests every 3 weeks and tumor assessments every 6 weeks.

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, certain medications like high-dose aspirin, some anticoagulants, and systemic immunosuppressive medications are restricted. It's best to discuss your current medications with the trial team to see if any adjustments are needed.

What data supports the effectiveness of the drug combination Bevacizumab, Atezolizumab, and chemotherapy for small cell lung cancer?

Research shows that adding atezolizumab to chemotherapy improves survival in patients with extensive-stage small cell lung cancer. Additionally, combining atezolizumab and bevacizumab with chemotherapy has shown effectiveness in treating other types of lung cancer, suggesting potential benefits for small cell lung cancer as well.12345

Is the combination of Bevacizumab, Chemoimmunotherapy, and Atezolizumab generally safe for humans?

Bevacizumab, also known as Avastin, has been studied for safety in various cancers, including non-small cell lung cancer. Common side effects include bleeding, high blood pressure, and protein in the urine, but these are usually manageable with standard care. Serious side effects are rare, and the treatment is generally considered safe when monitored properly.678910

How is the drug Bevacizumab + Chemoimmunotherapy + Atezolizumab unique for treating small cell lung cancer?

This treatment is unique because it combines bevacizumab, which blocks blood vessel growth that tumors need, with atezolizumab, an immune therapy that helps the body attack cancer cells, and chemotherapy, offering a multi-faceted approach to treating small cell lung cancer.311121314

Research Team

KS

Kamya Sankar, MD

Principal Investigator

Cedars-Sinai Cancer

Eligibility Criteria

This trial is for adults with extensive-stage small cell lung cancer (ES-SCLC) that has spread to the liver. They should not have had prior treatment for ES-SCLC, be in a stable condition (ECOG 0-2), and able to follow study procedures. Women must use birth control, and men agree to use condoms. People with certain health conditions or who've had specific treatments recently are excluded.

Inclusion Criteria

My EGFR mutant lung cancer has changed to small cell type and spread to my liver, and I haven't had chemotherapy or immunotherapy.
Women who could become pregnant must have a negative pregnancy test.
I have not been treated for extensive-stage small cell lung cancer before.
See 8 more

Exclusion Criteria

I have not received any live vaccines recently.
I have not had major surgery in the last 4 weeks.
I have not coughed up blood in the last month.
See 29 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction

Bevacizumab is administered in combination with atezolizumab and chemotherapy on a 21-day cycle for four cycles

12 weeks
4 visits (in-person)

Maintenance

Atezolizumab and bevacizumab are administered every 21 days for up to 12 months, or until unacceptable toxicity or disease progression

12 months
16 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Bevacizumab
Trial OverviewThe trial tests if adding Bevacizumab to Atezolizumab plus chemotherapy improves how long patients with ES-SCLC and liver metastases live without their cancer getting worse. It includes an induction phase of all drugs for four cycles, followed by maintenance therapy up to 12 months or until side effects become too severe or the disease progresses.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Experimental TreatmentExperimental Treatment1 Intervention
1. Induction (ABCE): Atezolizumab 1200 mg, Bevacizumab 15 mg/kg, Carboplatin AUC5, Etoposide 100 mg/m2, given IV Q3weeks 2. Maintenance (AB): Atezolizumab 1200 mg and Bevacizumab 15 mg/kg given IV Q3weeks for 1 year, or until disease progression, or unacceptable toxicity

Bevacizumab is already approved in European Union, United States, Japan, Canada for the following indications:

🇪🇺
Approved in European Union as Avastin for:
  • Colorectal cancer
  • Breast cancer
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Ovarian cancer
🇺🇸
Approved in United States as Avastin for:
  • Colorectal cancer
  • Non-small cell lung cancer
  • Glioblastoma
  • Renal cell carcinoma
  • Cervical cancer
  • Ovarian cancer
🇯🇵
Approved in Japan as Avastin for:
  • Colorectal cancer
  • Non-small cell lung cancer
  • Breast cancer
  • Renal cell carcinoma
  • Ovarian cancer
🇨🇦
Approved in Canada as Avastin for:
  • Colorectal cancer
  • Non-small cell lung cancer
  • Breast cancer
  • Renal cell carcinoma
  • Ovarian cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Kamya Sankar

Lead Sponsor

Trials
1
Recruited
40+

University of Michigan

Collaborator

Trials
1,891
Recruited
6,458,000+

Genentech, Inc.

Industry Sponsor

Trials
1,578
Recruited
569,000+
Ashley Magargee profile image

Ashley Magargee

Genentech, Inc.

Chief Executive Officer since 2024

MBA from Harvard University, BA from Princeton University

Levi Garraway profile image

Levi Garraway

Genentech, Inc.

Chief Medical Officer since 2021

MD, PhD

VA Ann Arbor Healthcare System

Collaborator

Trials
19
Recruited
10,300+

Findings from Research

In a study of 518 patients with extensive small cell lung cancer (SCLC) receiving atezolizumab plus chemotherapy, the median overall survival was 11.3 months, with 46.7% of patients alive at 12 months, indicating the treatment's effectiveness in a real-world setting.
The study demonstrated that 23.6% of patients continued atezolizumab treatment beyond disease progression, suggesting a potential strategy for improving outcomes, particularly in patients with better performance status (PS 0/1) who had a median overall survival of 12.2 months.
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.Falchero, L., Guisier, F., Darrason, M., et al.[2023]
The combination of atezolizumab, a PD-L1 inhibitor, with platinum-based chemotherapy significantly improves overall survival in patients with extensive-stage small cell lung cancer compared to chemotherapy alone.
This research suggests that this combination therapy could become a new first-line treatment option for patients suffering from this aggressive form of lung cancer.
Study: Atezolizumab Improves Survival in SCLC.[2019]
In a phase 3 study involving 692 patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC), the combination of atezolizumab, bevacizumab, and chemotherapy significantly improved median progression-free survival to 8.3 months compared to 6.8 months with bevacizumab and chemotherapy alone.
The addition of atezolizumab also led to a longer median overall survival of 19.2 months versus 14.7 months in the control group, demonstrating its efficacy across various genetic backgrounds and PD-L1 expression levels.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.Socinski, MA., Jotte, RM., Cappuzzo, F., et al.[2022]

References

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study. [2023]
Study: Atezolizumab Improves Survival in SCLC. [2019]
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. [2022]
Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer. [2023]
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. [2022]
Emerging safety data for bevacizumab in advanced non-small-cell lung cancer. [2015]
Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. [2022]
Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials. [2022]
Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). [2015]
Understanding and managing the possible adverse effects associated with bevacizumab. [2020]
AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany. [2020]
[Bevacizumab in thoracic oncology: results and practical aspects]. [2015]
13.United Statespubmed.ncbi.nlm.nih.gov
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. [2023]
14.United Statespubmed.ncbi.nlm.nih.gov
Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. [2021]